SCHEMBL4639746

SCHEMBL4639746

CCCCn1c(=O)cc(N=CN(C)C)n(CC)c1=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
HPGD P15428 1/20 0.41
ADORA2B P29275 1/20 0.39
ALDH1A1 P00352 2/20 0.35
PDE4A P27815 3/20 0.34
ADORA2A P29274 3/20 0.34
PDE4B Q07343 3/20 0.34
PDE4C Q08493 3/20 0.34
PDE4D Q08499 3/20 0.34
RGS4 P49798 2/20 0.34
GSK3B P49841 1/20 0.34
RGS8 P57771 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
CNR2 P34972 2/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2C19 P33261 1/20 0.33
TSHR P16473 1/20 0.32
ADRA2A P08913 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2332943 0.94 LMNA (0.51) LMNASMN1; SMN2HPGDADORA2BALDH1A1
SCHEMBL240142 0.92 LMNA (0.51) LMNASMN1; SMN2HPGDADORA2BALDH1A1
SCHEMBL2756837 0.92 LMNA (0.51) LMNASMN1; SMN2HPGDADORA2BALDH1A1
SCHEMBL2333544 0.89 LMNA (0.52) LMNASMN1; SMN2HPGDADORA2BALDH1A1
SCHEMBL1944745 0.88 LMNA (0.53) LMNASMN1; SMN2HPGDALDH1A1PDE4A
SCHEMBL1945583 0.88 LMNA (0.53) LMNASMN1; SMN2HPGDALDH1A1PDE4A
SCHEMBL2331175 0.86 LMNA (0.53) LMNASMN1; SMN2HPGDADORA2BPDE4A
SCHEMBL1546128 0.81 LMNA (0.46) LMNASMN1; SMN2HPGDADORA2BALDH1A1
SCHEMBL1945918 0.80 LMNA (0.56) LMNASMN1; SMN2HPGDADORA2BALDH1A1
SCHEMBL2543060 0.80 LMNA (0.45) LMNASMN1; SMN2HPGDADORA2BALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1622908-B1 XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS INC (US) 2008-08-06 EP disclosed